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Parathyroid Tumor Biology in Familial Multiple Endocrine
Neoplasia Type 1: A Model for Cancer Development

Maria Luisa Brandi*

Familial multiple endocrine neoplasia type I (FMEN 1) is an autosomal dominant disorder
characterized by tumors of the parathyroid glands, pancreatic islets, and anterior pituitaiy.
Hyperplasia appears to be the typical histopathological lesion in FMEN 1 endocrine tumors. A
circulating mitogen related to basic fibroblast growth factor was active on proliferation of clonal
bovine and human parathyroid endothelial cells. Moreover, the FMEN 1 mitogen modulated
differentiation of human parathyroid endothelial cell in vitro. All these facts suggested that an
extrinsic factor was active on parathyroid endothelial cell growth and differentiation. The FMEN I
gene maps to chromosome I Iql3, and allelic loss in this region has been shown in FMEN 1
parathyroid and pancreatic islet tumors and rarely in anterior pituitary tumors. Together these
results support the theory that FMEN 1 parathyroid clonal lesions can develop in the context of
generalized hyperplasia. Similarly, in uremic hyperparathyroidism, where parathyroid hyperplasia
is thought to be the primary lesion, loss of constitutional heterozygosity for chromosome II markers
coexists in parathyroid tissue with a polyclonal pattern. Future efforts of scientists working on this
genetic disorder will focus on the cloning of the FMEN 1 gene and the development of a suitable
bioassay system to study its function. (Henry Ford Hosp Med J 1992;40:181-5)

D

uring the past seven years, we have been working on the
cellular biology of parathyroid tissue, with a particular interest in "hyperplastic" parathyroid tumors of patients affected
by familial multiple endocrine neoplasia type 1 (FMEN 1),
a disorder in which subjects develop not only hyperparathyroidism but also tumors of the pituitary glands and the endocrine
pancreas (1).
This model became important for understanding the significant events in parathyroid tumor development. We review the
progress of our laboratory and that of others in defining the molecular abnormalities of FMEN 1 endocrine tumors.

contribute to the generalized hyperplasia that precedes tumor
development in familial cancers. The stimulus for this polyclonal hyperplastic growth may refiect an intrinsic abnormality of
the target cell or else an extrinsic stimulus for the entire cell population. The second "hit" becomes manifest in occasional cells
via loss of the remaining normal gene allele. Subsequent clonal
tumor growth ensues from the cells that have suffered these two
hits. Tbis process is usually multifocal and each tumor comes
from a different cell clone (7). This multiplicity refiects the initial genetic abnormality of the hyperplastic cell population.

Pathology of FMEN 1 l\imors
Mechanisms Underlying Tiimor
Development in FMEN 1 Syndrome
DNA restriction fragment length polymorphism studies of
lymphocyte DNA have linked the germline genetic abnormality
for FMEN 1 to the long arm of chromosome 11 region ql3 (2).
It was initially proposed (2) that the mechanism of the tumorigenesis via the chromosome 11 in FMEN 1 tumors might be
similar to that of retinoblastoma (3) and of several other heritable cancers (4-6), where loss of a recessive tumor suppressor
function is thought to play the initial role in tumor development.
This theory is based on the "two hit" hypothesis of carcinogenesis developed by Knudson (3) for formation of retinoblastoma. In the familial form of retinoblastoma, the first "hit" is a
germline genetic defect which is assumed to be phenotypically
silent as long as the normal allele is functionally intact. Altematively, the first hit in target tissues might not be silent but may
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The tumors in FMEN 1 syndrome tend to be multiple in the
involved organ. Moreover, even though FMEN 1 syndrome has
a generalized hyperplastic phase (8), a complete spectmm of hyperplasia, microadenomas, adenomas, carcinomas, and carcinoid changes have been found on pathological examination. In
FMEN 1 patients the major histologic abnormality is parathyroid hyperplasia. Gland size is markedly irregular in parathyroid
hyperplasia and sometimes one or even two of the glands can be
of normal weight. The nature of parathyroid lesions is usually
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cally, pituitary lesions can consist of chromophobe, eosinophil,
basophil, or mixed cell types.
Adrenal abnormalities in FMEN 1 syndrome generally consist of diffuse or nodular hyperplasia. Occasionally there may be
a cortical adenoma or even carcinoma. In only a few cases does
the clinical history indicate that the tumors have functioned.
The pattem of thyroid involvement is inconsistent. Thyroid
adenoma, colloid goiter, thyroid carcinoma, and thyrotoxicosis
have been reported.
Primary carcinoids of the bronchus and thymus do not differ
from sporadic tumors, while carcinoids of the gastric mucosa
are characterized by multicentricity. Indeed, hyperplasia of argyrophil endocrine cells is regularly noted in the hypertrophic
oxyntic mucosa of Zollinger-Ellison patients, a finding generally attributed to the trophic action of gastrin on the main type of
endocrine cell located in this mucosa, the so-called enterochromaffin-like (ECL) cell (9). In addition to ECL hyperplasia, tumors of this cell type having the morphological appearance of
carcinoids arise frequendy in patients with gastrinoma in the
setting of FMEN 1 syndrome (10). These findings have been interpreted as an effect of gastrin upon genetically altered ECL
cells to promote tumor growth.
Tumors of FMEN 1 patients have been extensively characterized by morphologists; however, only limited data are available
on preneoplastic lesions developing in man. Transgenic mice
bearing tumors of the anterior pituitary and pancreas have been
proposed as useful tools to improve our understanding of heritable endocrine tumor disease in human pathology (11). The morphological steps of tumor development in these animals were
analyzed and preneoplastic features were described. Hyperplasia together with dysplasia and dysplasia without hyperplasia
were the lesions preceding tumor formation in these transgenic
animals (11).
Fig I—Primary cultures of FMEN I glucagonoma tissue. Cells
were culturedfor seven (A) and 30(B) days in Coon's modified
Ham's F12 medium containing 10% FCS. Original magnification X250.

that of chief cell hyperplasia. Nevertheless, a number of FMEN
1 patients have been reported with one or more parathyroid adenomas. However, proof of long-term cure of hyperparathyroidism following removal of a single parathyroid adenoma is
rarely found in FMEN 1. These observations are suggestive of
the coexistence of both forms of parathyroid disease, adenoma
and hyperplasia, in the same genetic setting.
Similar to the lesions in the parathyroid glands, the abnormalities in the islet cells in the FMEN 1 syndrome consist of diffuse
hyperplasia, affecting either a single type of cell or two or more
different types. The endocrine pancreas in FMEN 1 syndrome
displays single or multiple benign or malignant islet cell neoplasms.
In patients with the FMEN 1 syndrome, the anterior pituitary
lesion is commonly an adenoma, generally solitary. However,
multiple pituitary tumors with increased plasma prolactin and
growth hormone concentrations have been reported. Histologi-
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Cell Biology of FMEN 1 Tiimors
Studies with cell cultures have begun to clarify some of the
mechanisms which underlie growth dysfunction in the parathyroid tissue. This progress has been mainly due to the development of rat epithelial (12) and bovine endothelial (13) clonal cell
lines from parathyroid tissue. The use of such in vitro models
made it possible to demonstrate that a mitogen closely related to
basic fibroblast growth factor (bFGF) is circulating at high concentrations in FMEN 1 syndrome (14,15). Bovine parathyroid
endothelial cells represented a target for this growth factor, suggesting the possibility that a bFGF-like factor may act systemically on parathyroid angiogenesis and, therefore, indirectly on
proliferation of the epithelial component of parathyroid tissue.
We have also shown that bovine parathyroid endothelial cells
release factor(s) able to stimulate proliferation of rat parathyroid
epithelial cells and vice versa (16). These observations pointed
to the importance of considering the stromal cells of the endocrine tissue as active components of the metabolic activities of
the glands. Moreover, these findings suggested the possibility
that a soluble endothelial cell growth factor may play a critical
role in the growth of the parathyroid tissue in FMEN 1, supporting the hypothesis of a generalized polyclonal proliferation of
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the glands. However, the main limitation of our studies was the
lack of human cell models to evaluate the mechanisms -which
underlie cell proliferation and cell to cell interactions in the endocrine organs involved in the FMEN 1 syndrome. We have,
therefore, developed both primary cultures as well as clonal cell
lines from FMEN 1 endocrine tumors.
Primary cultures are an ideal system for in vitro studies on
cell differentiation, refiecting well the in vivo tissue heterogeneity. However, this cellular heterogeneity is also the main cause
of cell culture variability observed in multiple experiments. In
fact, depending on the composition of the tissue of origin (ratio
of stromal/epithelial components, etc.) and also on the tissue
manipulation (enzyme digestion, adhesion properties, growth
capability, etc.), great heterogeneity exists between one tissue
preparation and the other. Moreover, primary cultures are destined to be overgrown by fibroblast-like cells (Fig 1 [A and B])
and therefore the epithelial component has a limited life span.
Even though all ofthese limitations must be considered, preliminary studies using primary cultures of FMEN 1 endocrine tissue appear promising. Parathyroid cells obtained from FMEN 1
parathyroid tissue and cultured for seven days in the presence of
10% fetal calf serum (FCS) exhibited an epithelial morphology
with a tendency to not proliferate (Fig 2A). The replacement of
FCS with 10% MEN 1 plasma induced cell proliferation and
spreading (Fig 2B). We have also developed primary cultures
from pancreatic islet tumors of patients with FMEN 1 syndrome. In our experience pancreatic endocrine cells adhere to
the plastic dishes (Fig 1 A) or could be maintained as suspension
cultures (Fig 3). Primary cultures of FMEN 1 pituitary tissue
formed clusters remini.scent of the pituitary follicular cells (Fig
4).
Recentiy, we have cloned an endothelial (HPE) cell line from
FMEN 1 parathyroid tissue. The fact that the bovine parathyroid
endothelium was the target of the mitogenic effect of the bFGFlike mitogen (14,15) prompted further tests on the newly developed human cell line. Preliminary results showed clearly not
only a potent proliferative effect of FMEN 1 plasma on HPE cell
proliferation, but also an induction of endothelial differentiative
features required in angiogenesis. The growth of new capillaries, whether in development, wound healing, tumor angiogenesis, arthritis, or diabetes, requires lumen formation and migration of endothelial cells. Confiuent HPE cells cultured in the
presence of 10% FMEN 1 plasma exhibited a pecuhar "ring"
shape (Fig 5). This morphological correlate may indicate a role
ofthe FMEN 1 plasma in the lumen formation via vacuolization
ofthe endothelial cells or else by cylindrical curvature of the cell
membrane. When HPE cells were incubated in medium containing FCS they either remained quiescent or moved slowly. In response to different concentrations of FMEN 1 plasma, the rate
of cell migration, measured as the surface of the tracks made by
the cells as they migrated across gold-coated coverslips, increased proportionately.

Genetics of FMEN 1 Tumors
The mapping of the FMEN 1 gene to chromosome 11 and the
implication of the inactivation of negative modulation in the
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Fig 2—Primary cultures of FMEN I parathyroid tissue. Cells
were culturedfor seven days in Coon's modified Ham's F12 medium containing 10% FCS (A) and 10% FMEN 1 plasma (B).
Original magnification X250.

pancreatic growth disturbance in FMEN 1 (2) prompted further
studies on loss of constitutional heterozygosity in FMEN 1 endocrine tumors.
Loss of DNA alleles from one copy of the long arm of chromosome 11 region q 13 has been found in both sporadic and
FMEN 1 associated tumors (17-20). These results are in agreement with the two-mutational model. In sporadic tumors the
loss of constitutional heterozygosity is indirect evidence of
monoclonahty. However, in familial hyperplasia such losses do
not necessarily refiect a monoclonal composition of the tumor.
Since these losses serve to eliminate the wild type allele at the
disease locus, polyclonal and monoclonal tumors may give similar pattems of allele losses for chromosome 11 markers. Interestingly, allelic losses specific to chromosome 11 are typical of
the larger FMEN 1-associated parathyroid lesions (17), suggesting that clonal outgrowth might arise in the context of generalized hyperplasia in FMEN 1 parathyroid tissue. In order to better
understand the relationships between clonal lesions and hyperplasia in FMEN 1 parathyroid tumors, we have chosen the
model of uremic hyperparathyroidism, believed to be hyperplastic in origin. We found loss of constitutional heterozygosity

Biology of FMEN 1 Parathyroid Tumors—Brandi

183

Fig 3—Primary cultures of FMEN I insulinoma. Cells were cultured in Coon's modified Ham's F12 medium containing 10%
FCS. Several cells grew in suspension. Small clusters of adherent cells (arrows] as well as "ring" structures (arrowheads) are
represented. Original magnification X250.

Fig 4—Primary cultures of FMEN I prolactinoma. Cells were
cultured in Coon's modified Ham's F12 medium containing
10% FCS. Cells formed thick clusters (arrowhead and inset) resembling the follicle-like structures described in primary cultures of bovine pituitary cells. Original magnification X250 and
X400 (inset).
for chromosome 11 markers in two of nine glands from five
uremic patients (21). Interestingly, the two glands with allelic
losses were significantly greater in mass than those without loss,
supporting the dieory that parathyroid adenoma can develop
through overgrowth by a monoclonal tumor in the context of
generalized hyperplasia. Parathyroid lesions have represented a
rich opportunity to study molecular changes that occur during
tumor development. However, the lack of correlation between
standard histopathology (hyperplasia versus adenoma) and molecular biology (polyclonal versus monoclonal lesions) studies
makes it desirable to prepare DNA from microscopic sections of
tumors, where contiguous sections would be analyzed by histopathology.
Loss of constitutional heterozygosity has been found also in
FMEN 1 pancreatic islet cell hyperplasia and in insulinomas
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Fig 5—Clonal HPE cells maintained in culture for 20 days in
Coon's modified Ham's FI2 containing 10% FMEN 1 plasma.
Cells exhibited a typical "ring" shape. Original magnification
X400.
(2,22). In contrast to parathyroid tumors, many sporadic pancreatic islet neoplasms, even when malignant, do not develop
through homozygous inactivation of the FMEN 1 gene (22).
The FMEN 1 pituitary lesions are most commonly prolactinomas, a tumor which is only rarely managed by surgical intervention. Therefore, studies of loss of heterozygosity in pituitary
tumors have been comprised mainly of sporadic pituitary tumors (19). The observation of relatively few allelic losses on
chromosome 11 in FMEN 1 or sporadic pituitary adenomas suggested that the recessive nature of the germline defect proposed
for FMEN 1 parathyroid and pancreatic tissues might not be operative in pituitary tumors.
Finally, FMEN 1 bronchial carcinoid (22), FMEN 1 benign
adrenal enlargements, and sporadic adrenocortical adenomas
showed retained genotypes for markersfiankingthe FMEN 1 region.
An altemative explanation for the low incidence for reduction
of homozygosity in a number of FMEN 1 endocrine tumors
should be given serious consideration. The two allelic hit theory
of Knudson (3) might not be operative in these tumors. However, it is also conceivable that failure to detect reduction of homozygosity might be due to a mechanism of inactivation of the
normal allele function that does not involve the loss of a large
segment of chromosome 11 (i.e., point mutations). Altematively, subsequent genetic events necessary for frank neoplasm
formation may involve not the opposite normal allele but other
genetic loci, as suggested in Wilm's tumor (23,24).

Cytogenetics of FMEN 1 l\imors
One important line of evidence in support of a genetic origin
for cancer is the frequent finding of chromosomal abnormalities
in patients with specific types of tumor. Perhaps the best characterized of these are deletions involving the chromosome region
13ql4, which are found in tumortissueof 5% of cases of retinoblastoma with normal constitutional karyotypes. Initially,
karyotype analysis in FMEN 1 patients resulted in an inconsis-
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tent pattem of chromosomal instability in family members with
the FMEN 1 syndrome (25). Recentiy, analysis of cultured lymphocytes and fibroblasts of FMEN 1 patients showed a number
of chromosome abnormalities with no rearrangements involving chromosome 11 (26). Similarly, primary cultures of FMEN
1 pancreatic tumors revealed a number of chromosome abnormalities with .several double minute chromosomes of variable
size and no specific involvement of chromosome 11 (27).

Prospects
Cleariy, elucidation ofthe genetic events that underlie the development of tumors in FMEN 1 will teach much about the
range of molecular changes that can contribute to the early
stages of human cancer. Cytogenetic, cellular, and molecular biology studies of FMEN 1 tumors will contribute to this understanding. The immediate goal of several laboratories is the cloning of the FMEN 1 gene. However, a biologic assay for the
FMEN 1 gene function would be the ultimate proof of its suppressor nature, similariy to what developed for the retinoblastoma gene (28). This will allow introduction of the gene into
cultured tumor cells that contain inactivated endogenous FMEN
1 genes. Therefore, the development of an assay system for the
FMEN 1 gene function remains an important goal.

Acknowledgments
This work was supported by the Progetto Finalizzato CNR
"Inge gneria Genetica" and by the Associazione Italiana per la
Ricerca sul Cancro.

References
1. Wermer P. Genetic aspects of adenomatosis of endocrine glands. Am J Med
1954; 16:36.3-71.
2. Larsson C. Skog.seid B, Oberg E. Nakamura Y, Nordenskjold M. Multiple
endocrine neoplasia type I gene maps to chromosome 11 and is lost in insulinoma. Nature 1988;332:85-7.
3. Knudson AG. Mutation and cancer: Statistical study of retinoblastoma.
Proc Natl Acad Sci USA 1971;68:820-3.
4. Seizinger BR. Manuza RL. Gu.sella JF. Loss of genes on chromosome 22 in
tumorigenesis of human acoustic neuroma. Nature 1986;322:644-7.
5. Green AR. Recessive mechanisms of malignancy. Br J Cancer 1988;
58:115-21.
6. Ponder B. Gene los.ses in human tumours. Nature 1988;335:400-2.
7. Baylin SB. Hsu SH. Gann DS, Smallridge RC, Wells SA Jr. Inherited
medullary thyroid carcinoma: A final n-ionoclonal mutation in one of multiple
clones of susceptible cells. Science 1978;199:429-31.
8. Ballard HS. Frame B. Hart.sock RJ. Familial multiple endocrine adenomapeptic ulcer complex. Medicine (Baltimore) 1964;43:481-516.
9. Hakanson E. Ekelund M, Sundler F. Activation and proliferation of gastric
endocrine cells. In: Falkmer S, Hakanson R. Sundler F. eds. Evolution & tumour
pathology of the neuroendocrine system. Amsterdam: Elsevier, 1984:37198.
10. Solcia E, Capella C, Fiocca R, Rindi G, Rosai J. Gastric argyrophil
carcinoidosis in patients with Zollinger-Ellison syndrome due to type 1 multiple

Henry Ford Hosp Med J—Vol 40, Nos 3 & 4, 1992

endocrine neoplasia: A newly recognized association. Am J Surg Pathol
1990;14:503-13.
11. Rindi G. Bishop AE, Murphy D, Solcia E, Hogan B, Polak JM. A morphological analysis endocrine tumour genesis in pancreas and anterior pituitary of
AVP/SV40 tran.sgenic mice. Virchows Archiv [A] I988;412;255-66.
12. Sakaguchi K. Santora A, Zimering M, Curcio F, Aurbach GD, Brandi ML.
Functional epithelial cell line cloned from rat parathyroid glands. Proc Natl Acad
Sci USA 1987;84:3269-73.
13. Brandi ML, Ornberg RL, Sakaguchi K, et al. Establishment and characterization of a clonal line of parathyroid endothelial cells. FASEB 1990:4:31528.
14. Brandi ML, Zimering MB, Marx SJ, et al. Multiple endocrine neoplasia
type I : Role of a circulating factor in parathyroid cell hyperplasia. In: Kleerekoper M. Ki-ane SM. eds. Clinical disorders of bone and mineral metabolism. New
York City: Mary Ann Liebert, Inc., 1989:323-8.
15. Zimering MB. Brandi ML. DeGrange DA. et al. Circulating fibroblast
growth factor-like substance in familial multiple endocrine neoplasia type 1. J
Clin Endocrinol Metab 1990;70:149-.54.
16. Brandi ML. Sakaguchi K. Curcio F, Omberg RL, Leikes PI, Aurbach GD.
Social behavior of parathyroid epithelial (PT-r) and endothelial (BPE-1) cells in
co-culture. J Bone Min Res I988;3:S2II.
17. Friedman E, Sakaguchi K, Bale AE, et al. Clonality of parathyroid tumors
in familial multiple endocrine neoplasia type 1. N Engl J Med 1989;321;2138.
18. Thakker RJ. Bouloux P. Wooding C, et al. Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome
II.NEnglJMed 1989;321:218-24.
19. Bystrom C, Larsson C, Blomberg C, etal, Ijjcalization ofthe MENl gene
to a small region within chromosome 11 q 13 by deletion mapping in tumors. Proc
Natl Acad Sci USA 1990;87:1968-72.
20. Radford DM. Ashley SW. Wells SA Jr, Gerhard DS, Loss of heterozygosity of markers on chromosome 11 in tumors from patients with multiple endocrine neoplasia syndrome type 1. Cancer Res 1990;50:6529-33.
21. Falchetti A, Bale AE, Amoros A, et al. Allelic loss in the multiple endocrine neoplasia type 1 (MEN 1) region of chromosome 11 in uremic parathyroidism (Abstract). Am J Hum Genet 1991:49:120.
22. Bale AE. Norton JA, Wong EL, et al. Allelic loss on chromo.some 11 in
hereditary and sporadic tumors related to familial multiple endocrine neoplasia
type 1. Cancer Res 1991 ;51:1154-7.
23. Grundy P, Koufos A, Morgan K, Li FP. Meadows AT. Cavenee WK. Familial predisposition to Wilms' tumour does not map to the short arm of chromosome 11. Nature 1988;336:374-6.
24. Huff V, Compton DA. Chao L-Y, Strong LC. Geiser CF, Saunders GF.
Lack of linkage of familial Wilms' tumourto chromosomal band 1 lpl3. Nature
1988;336:377-8.
25. Benson L. Gustavson KH, Rastad J, Akerstrom G, Obei-g K, Ljunghall S,
Cytogenetical investigations in patients with primary hyperparathyroidism and
n-iultiple endocrine neoplasia type 1. Hereditas 1988;108:227-9.
26. Scappaticci S, Maraschio P. del Ciotto N, Fossati GS, Zonta A, Fraccaro
M. Chi-omosome abnormalities in lymphocytes and fibroblasts of subjects with
multiple endocrine neoplasia type 1. Cancer Genet Cytogenet 1991:52:8592.
27. Scappaticci S, Brandi ML, Capra E, Cortinovis M, Maraschio P, Fraccaro
M. Cytogenetics of multiple endocrine neoplasia syndromes. II. Chromosome
abnorinalities in one insulinoma and one glucagonoma from two subjects with
MEN 1. Cancer Genet Cytogenet 1992;59:51-3.
28. Su Huang H-J, Yee J-K, Shew J-Y, et al. Suppression of the neoplastic
phenotype by replacement of the RB gene in human cancer cells. Science
1988;242:1563-6.

Biology of FMEN I Parathyroid Tumors—Brandi

185

